Roll over image to zoom in
Sunitix (Sutent) Sunitinib Malate 50mg online
$436.00
Status: In stock
the treatment of gastrointestinal stromal tumor (GIST) after disease progression on or intolerance to imatinib mesylate.
Sunitix (Sutent)Ā is a kinase inhibitor indicated for:
1. the treatment of gastrointestinal stromal tumor (GIST) after disease progression on or intolerance to imatinib mesylate.
2. the treatment of advanced renal cell carcinoma (RCC).
3. the adjuvant treatment of adult patients at high risk of recurrent RCC following nephrectomy.
4. the treatment of progressive, well-differentiated pancreatic neuroendocrine tumors (pNET) in patients with unrespectable locally advanced or metastatic disease.
DOSAGE AND ADMINISTRATION
GIST and Advanced RCC:
1. 50 mg orally once daily, with or without food, 4 weeks on treatment followed by 2 weeks off.
Adjuvant RCC:
2. 50 mg orally once daily, with or without food, 4 weeks on treatment followed by 2 weeks off for nine 6-week cycles.
pNET:
3. 37.5 mg orally once daily, with or without food, continuously without a scheduled off-treatment period.
Dose Modification:
Dose interruptions and/or dose adjustments of 12.5 mg recommended based on individual safety and tolerability.
Sunitixās brand name isĀ SutentĀ®by Pfizer.Ā SunitixĀ is a genericĀ is a kinase inhibitorĀ from Beacon, which is one of the biggest pharmaceutical company in Bangladesh.
For more Prescribing informationļ¼please check theĀ āĀ āFDAĀ Prescribing Informationā.
1. the treatment of gastrointestinal stromal tumor (GIST) after disease progression on or intolerance to imatinib mesylate.
2. the treatment of advanced renal cell carcinoma (RCC).
3. the adjuvant treatment of adult patients at high risk of recurrent RCC following nephrectomy.
4. the treatment of progressive, well-differentiated pancreatic neuroendocrine tumors (pNET) in patients with unrespectable locally advanced or metastatic disease.
DOSAGE AND ADMINISTRATION
GIST and Advanced RCC:
1. 50 mg orally once daily, with or without food, 4 weeks on treatment followed by 2 weeks off.
Adjuvant RCC:
2. 50 mg orally once daily, with or without food, 4 weeks on treatment followed by 2 weeks off for nine 6-week cycles.
pNET:
3. 37.5 mg orally once daily, with or without food, continuously without a scheduled off-treatment period.
Dose Modification:
Dose interruptions and/or dose adjustments of 12.5 mg recommended based on individual safety and tolerability.
Sunitixās brand name isĀ SutentĀ®by Pfizer.Ā SunitixĀ is a genericĀ is a kinase inhibitorĀ from Beacon, which is one of the biggest pharmaceutical company in Bangladesh.
For more Prescribing informationļ¼please check theĀ āĀ āFDAĀ Prescribing Informationā.
Related products
Recently Viewed Products
